Prescient Therapeutics (FRA:UDD) Research & Development: €4.24 Mil (TTM As of Dec. 2025)


FRA:UDD Prescient Therapeutics Ltd FRA:UDD
22 GF Score
Price €0.03
! 2 Warning Signs
View Full Analysis

What is Prescient Therapeutics Research & Development?

Prescient Therapeutics FRA:UDD +1.64% 22 Research & Development is €4.24 Mil as of Dec. 2025. GuruFocus rates FRA:UDD with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Prescient Therapeutics's Research & Development for the six months ended in Dec. 2025 was €1.41 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €4.24 Mil.

Prescient Therapeutics  (FRA:UDD) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Prescient Therapeutics Research & Development Related Terms

Prescient Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Prescient Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prescient Therapeutics Research & Development Chart

Prescient Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.58 2.26 3.85 4.30 3.79

Prescient Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.49 1.80 1.03 2.83 1.41
FRA:UDD
22GF Score
Prescient Therapeutics Ltd FRA:UDD
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prescient Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €4.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €4.24 Mil mean?
Prescient Therapeutics (FRA:UDD) has a Research & Development of €4.24 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Prescient Therapeutics and its competitors.
Is Prescient Therapeutics' Research & Development too high?
Prescient Therapeutics' current Research & Development is €4.24 Mil. Overall, Prescient Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Prescient Therapeutics' Research & Development compare to VRTX and REGN?
Prescient Therapeutics' Research & Development of €4.24 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Prescient Therapeutics and its competitors. Prescient Therapeutics's current Research & Development is €4.24 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prescient Therapeutics stock overvalued right now?
Prescient Therapeutics (FRA:UDD) has a current Research & Development of €4.24 Mil. The current Research & Development is €4.24 Mil. Prescient Therapeutics' overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Prescient Therapeutics (FRA:UDD), the current Research & Development is €4.24 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Prescient Therapeutics Business Description

Other Exchanges PTX:Australia
Address 385 Bourke Street, Suite 2, Level 11, Melbourne, VIC, AUS, 3200
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.
22GF Score

Get the complete analysis for FRA:UDD

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.03
Price